Fluid Administration in Emergency Room Limited by Lung Ultrasound in Patients with Sepsis: Protocol for a Prospective Phase II Multicenter Randomized Controlled Trial
Abstract:Background
Sepsis remains a major health challenge with high mortality. Adequate volume administration is fundamental for a successful outcome. However, individual fluid needs differ between patients due to varying degrees of systemic vasodilation, circulatory flow maldistribution, and increased vascular permeability. The current fluid resuscitation practice has been questioned. Fluid overload is associated with higher mortality in sepsis. A sign of fluid overload is extravascular lung water, seen … Show more
“…Eight eligible trials are still ongoing, but not included because the results are not yet available. 36 , 37 , 38 , 39 , 40 , 41 , 42 , 46 A total of 4,006 patients were randomized in the 13 included RCTs ( Fig 1 ). 11 , 12 , 13 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 35 …”
“…Eight eligible trials are still ongoing, but not included because the results are not yet available. 36 , 37 , 38 , 39 , 40 , 41 , 42 , 46 A total of 4,006 patients were randomized in the 13 included RCTs ( Fig 1 ). 11 , 12 , 13 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 35 …”
“…Nevertheless, it is important to follow and thoroughly register initial fluid volumes to assess clinical implications. Evidence from ongoing trials will provide data on the potential effects of initial fluid volumes 28–35 …”
Section: Discussionmentioning
confidence: 99%
“…Evidence from ongoing trials will provide data on the potential effects of initial fluid volumes. [28][29][30][31][32][33][34][35] This study has strengths, including those of the CLASSIC trial, that is, international recruitment, large sample size and high levels of data completeness. 4 This was a pre-planned secondary study where the protocol and statistical analysis plan were submitted for publication before closing the CLASSIC trial database.…”
Section: Heterogeneity Of Treatment Effectsmentioning
BackgroundThe CLASSIC trial assessed the effects of restrictive versus standard intravenous (IV) fluid therapy in adult intensive care unit (ICU) patients with septic shock. This pre‐planned study provides a probabilistic interpretation and evaluates heterogeneity in treatment effects (HTE).MethodsWe analysed mortality, serious adverse events (SAEs), serious adverse reactions (SARs) and days alive without life‐support within 90 days using Bayesian models with weakly informative priors. HTE on mortality was assessed according to five baseline variables: disease severity, vasopressor dose, lactate levels, creatinine values and IV fluid volumes given before randomisation.ResultsThe absolute difference in mortality was 0.2%‐points (95% credible interval: −5.0 to 5.4; 47% posterior probability of benefit [risk difference <0.0%‐points]) with restrictive IV fluid. The posterior probabilities of benefits with restrictive IV fluid were 72% for SAEs, 52% for SARs and 61% for days alive without life‐support. The posterior probabilities of no clinically important differences (absolute risk difference ≤2%‐points) between the groups were 56% for mortality, 49% for SAEs, 90% for SARs and 38% for days alive without life‐support. There was 97% probability of HTE for previous IV fluid volumes analysed continuously, that is, potentially relatively lower mortality of restrictive IV fluids with higher previous IV fluids. No substantial evidence of HTE was found in the other analyses.ConclusionWe could not rule out clinically important effects of restrictive IV fluid therapy on mortality, SAEs or days alive without life‐support, but substantial effects on SARs were unlikely. IV fluids given before randomisation might interact with IV fluid strategy.
“…Despite significant advances in the understanding of the physiology behind fluid therapy, hemodynamically unstable human and veterinary ECC patients often receive IV fluids without defining clear end points of fluid resuscitation or start points for fluid removal (132). Failure to identify end points of fluid resuscitation may lead to fluid overload and increased EVLW (45,(132)(133)(134). Evidence suggests that increased EVLW can be detected with lung ultrasound (LUS) through the identification of increased B lines: comparison of a reference standard for detection of EVLW and LUS for detection of increased B lines shows there is a direct correlation between the two (135)(136)(137), and evidence in humans shows the sensitivity and specificity of LUS to identify pulmonary edema (defined as increased B lines) is as high as 97 and 95%, respectively.…”
Section: Lung Ultrasound and Other Pocus Findings Suggestive Of Volume Overloadmentioning
Intravenous fluids are an essential component of shock management in human and veterinary emergency and critical care to increase cardiac output and improve tissue perfusion. Unfortunately, there are very few evidence-based guidelines to help direct fluid therapy in the clinical setting. Giving insufficient fluids and/or administering fluids too slowly to hypotensive patients with hypovolemia can contribute to continued hypoperfusion and increased morbidity and mortality. Similarly, giving excessive fluids to a volume unresponsive patient can contribute to volume overload and can equally increase morbidity and mortality. Therefore, assessing a patient's volume status and fluid responsiveness, and monitoring patient's response to fluid administration is critical in maintaining the balance between meeting a patient's fluid needs vs. contributing to complications of volume overload. This article will focus on the physiology behind fluid responsiveness and the methodologies used to estimate volume status and fluid responsiveness in the clinical setting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.